



10-21-04

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicant(s) : GHOSHAL, et al.  
Serial No. : 10/622,254  
Filed : July 18, 2003  
Title : Ecstasy-Class Derivatives, Immunogens, and Antibodies and Their Use in  
Detecting Ecstasy-Class Drugs  
Docket : RDID02024US  
Art Unit : 1645  
Customer No : 23690

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

"Express Mail" Label No. EV421106229US

Date of Deposit: October 20, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Michael R. Wilson

Signature of person mailing paper or fee

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.56, 1.97 & 1.98

Applicants submit herewith patents, publications, and other information of which he is they are aware, which they believe may be material, as defined in 37 CFR §1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 CFR §1.97(h), constitute an admission that any patent, publication, or other information referred to is, or is considered to be, material to the patentability of this invention. No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 & 103, and Applicants reserve the right, pursuant to 37 CFR §1.131 or otherwise, to establish otherwise. Further, pursuant to 37 CFR §1.97(g), the filing of this Statement should not be construed as a statement that a search has been made or that no other material information exists.


Serial No. 10/622,254  
RDID02024US

This Information Disclosure Statement is being filed within the period set forth in 37 CFR §1.97(b) because it is believed to be filed before the mailing date of a first office action on the merits.

The Office has waived the requirement pursuant to 37 CFR §1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC §371 after June 30, 2003. Therefore, no copies of each cited U.S. patent and each cited U.S. patent application publication are enclosed, but the cited U.S. patents and the cited U.S. patent application publications are listed on PTO/SB/08A.

No additional fees are believed to be necessary, however, should any fees be deemed required, the Commissioner is authorized to charge such fees to Deposit Account 02-2958, but is not to include any payment of issue fees.

Respectfully submitted,  
ROCHE DIAGNOSTICS OPERATIONS, INC.

By   
Marilyn L. Amick  
Registration No. 30,444

9115 Hague Road, P.O. Box 50416  
Indianapolis, IN 46250-0416  
Telephone: (317) 521-7561  
Facsimile: (317) 521-2883

Encls.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary) 	Docket Number (Optional) <b>RDID 02024 US</b>	Application Number <b>10/622,254</b>
	Applicants(s) <b>Ghoshal et al</b>	
	Filing Date: <b>7/18/03</b>	Group Art Unit: <b>1645</b>

U.S. PATENT DOCUMENTS							
Examiner Initials	Ref	Document Number	Date	Name	Class	Subclass	Filing Date (If Appropriate)
		4,041,076	8/9/1977	Avenia et al.	260	559	
		5,470,997	11/28/1995	Buechler et al.	558	254	

FOREIGN PATENT DOCUMENTS							
	Ref	Document Number	Date	Country	Class	Subclass	Translation

Other Documents (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Hadri, A. El et al., "Synthesis and bovine Beta3-adrenergic agonistic activities of a novel series of aryloxypropanolamines," Pharmazie, Vol. 56, No. 7, 2001, pp. 517-522					

Examiner	Date Considered
----------	-----------------